|
|
Volumn 60, Issue 570, 2010, Pages 50-52
|
|
Does higher usage of low-cost statins correlate with a poorer achievement in cholesterol quality markers for secondary prevention?
|
|
Author keywords
Cholesterol; Hydroxymethylglutaryl CoA reductase inhibitors; Quality and outcomes framework; Quality indicators; Secondary prevention; Statins
|
|
Indexed keywords
CHOLESTEROL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
PRAVASTATIN;
SIMVASTATIN;
ARTICLE;
CHOLESTEROL BLOOD LEVEL;
CONTROLLED STUDY;
COST BENEFIT ANALYSIS;
DRUG COST;
DRUG UTILIZATION;
GENERAL PRACTICE;
HEALTH CARE QUALITY;
HEALTH SERVICES RESEARCH;
PRESCRIPTION;
SECONDARY PREVENTION;
UTILIZATION REVIEW;
CARDIOVASCULAR DISEASES;
DRUG COSTS;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE);
PRAVASTATIN;
SECONDARY PREVENTION;
SIMVASTATIN;
STROKE;
|
|
EID: 76049096858
PISSN: 09601643
EISSN: None
Source Type: Journal
DOI: 10.3399/bjgp10X482112 Document Type: Article |
|
Times cited : (3)
|
|
References (6)
|
